Sorry, you need to enable JavaScript to visit this website.

INSPRA (eplerenone) Contraindications

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.


INSPRA (eplerenone) is contraindicated in all patients with the following:

  • hypersensitivity to INSPRA or any component of this medication (for a complete listing of the INSPRA components, see DOSAGE FORMS, COMPOSITION AND PACKAGING);
  • patients with clinically significant hyperkalemia;
  • severe hepatic impairment (Child-Pugh Class C);
  • serum potassium >5.0 mmol/L at initiation;
  • severe renal impairment [eGFR <30 mL/min/1.73 m2];
  • concomitant use with potassium-sparing diuretics, potassium supplements or strong CYP3A4 inhibitors such as ketoconazole, itraconazole, nefazodone, telithromycin, clarithromycin, ritonavir, and nelfinavir (see DRUG INTERACTIONS and DOSAGE AND ADMINISTRATION).

INSPRA (eplerenone) is also contraindicated for the treatment of hypertension in patients with:

  • type 2 diabetes with microalbuminuria
  • serum creatinine >132 µmol/L in males or > 115 µmol/L in females
  • moderate to severe renal impairment [eGFR<50 mL/min/1.73 m2]

What's New

No Current Announcements.

Contact Pfizer Medical Information

Report an Adverse Event
1 866 723-7111